Movement disorders

Movement Disorders Parkinson’s Epilepsy

Parkinson’s ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

The Parkinson Balancing Act Normal Balance Parkinson’s Disease Drug Therapy in Parkinson’s Acetylcholine Dopamine

Metabolism of Levodopa Levodopa 3,O-Methyldopa Dopamine Degradation products COMT COMT inhibitors

Treatment of Parkinson’s Amantadine, benztropin, diphenhydramine, trihexyphenidyl Miscellaneous Carbidopa-levodopa/entacapone (Stalevo) Increase DA & inhibit metabolism Selegiline(Eldepryl), Tolcapone (Tasmar), Entacapone (Comtan) Inhibit DA Metabolism Levodopa-carbidopa (Sinemet) Bromocriptine, Pergolide(Permax) Pramipexole(Mirapex), Ropinirole(Requip) Increase DA Stimulate DA receptors Agents Drug Action

Drug Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Clinical Management ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object]

Points to Ponder ,[object Object],[object Object],[object Object],[object Object],[object Object]

Epilepsy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Overview of Triggers ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Clinical Management of Epilepsy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Seizure Type by Incidence Generalized Tonic-Clonic Partial Other

MOA of Anticonvulsants ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Pharmacologic Agents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Management of Epilepsy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Movement disorders

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Ähnlich wie Movement disorders

Ähnlich wie Movement disorders (20)

Mehr von Diana Rangaves, PharmD, CEO

Mehr von Diana Rangaves, PharmD, CEO (20)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

Movement disorders